Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)

Diagnostic Microbiology and Infectious Disease
Paul R RhombergRonald N Jones

Abstract

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global, longitudinal antimicrobial resistance surveillance network of greater than 100 medical centers worldwide monitoring the susceptibility of bacterial pathogens to carbapenems and other broad-spectrum agents. Between 1999 and 2002, 15 US medical centers referred up to 200 nonduplicate isolates from clinical infections to a central processing laboratory. During this 4-year period, the antimicrobial activity of 11 broad-spectrum agents was assessed against 5389 bacterial isolates using Clinical and Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards)-recommended methods with interpretive criteria. Analysis of the MIC results for pathogens isolated from patients hospitalized in intensive care units (ICUs) were compared to results from pathogens isolated in non-ICU settings. Among Enterobacteriaceae (3884 strains), the carbapenems (imipenem and meropenem) demonstrated the highest susceptibility rates (> or =98.7%) and with only a 1% increase in resistance for ICU isolates compared to non-ICU organisms. Other antimicrobial agents tested demonstrated consistently higher susceptibility rates against Ente...Continue Reading

References

Sep 2, 2000·The Journal of Antimicrobial Chemotherapy·P J Turner
Jul 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S K FridkinUNKNOWN National Nosocomial Infections Surveillance (NNIS) System Hospitals
Jan 5, 2002·Diagnostic Microbiology and Infectious Disease·R N Jones, R Masterton
Jan 5, 2002·Diagnostic Microbiology and Infectious Disease·M A PfallerUNKNOWN MYSTIC Program Study Group
Jan 5, 2002·Diagnostic Microbiology and Infectious Disease·C MendesUNKNOWN MYSTIC Study Group (Europe)
Dec 4, 2002·The Journal of Antimicrobial Chemotherapy·Gunnar Kahlmeter, Derek F J Brown
Feb 18, 2003·JAMA : the Journal of the American Medical Association·Melinda M NeuhauserJohn P Quinn
Jun 7, 2003·International Journal of Antimicrobial Agents·J A A Hoogkamp-KorstanjeUNKNOWN Susceptibility Surveillance Study Group
Nov 18, 2003·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H Goossens
Apr 3, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G CornagliaUNKNOWN ESCMID Study Group for Antimicrobial Resistance Surveillance
Jun 25, 2004·The Journal of Antimicrobial Chemotherapy·Joan R BadiaAntoni Torres
Nov 4, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D M Livermore

❮ Previous
Next ❯

Citations

Apr 18, 2013·International Journal of Antimicrobial Agents·Syamhanin AdnanJason A Roberts
Jan 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseGeorge L Drusano
Apr 23, 2009·Critical Care Medicine·Jason A RobertsJeffrey Lipman
Feb 4, 2009·Antimicrobial Agents and Chemotherapy·Peter J PetersenPatricia A Bradford
Oct 26, 2011·Journal of Environmental Science and Health. Part. B, Pesticides, Food Contaminants, and Agricultural Wastes·Anna M Lenart
Aug 12, 2009·Infectious Disease Clinics of North America·Mary C Barsanti, Keith F Woeltje
Jul 23, 2015·American Journal of Respiratory and Critical Care Medicine·Joel M DulhuntyUNKNOWN BLING II Investigators for the ANZICS Clinical Trials Group *
May 20, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F B SimeJ A Roberts
Dec 14, 2007·Expert Opinion on Pharmacotherapy·David P Nicolau
Feb 24, 2015·Diagnostic Microbiology and Infectious Disease·Janattul-Ain JamalJason A Roberts
Sep 9, 2008·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Haridimos MarkogiannakisStilianos Katsaragakis
Mar 29, 2016·Expert Review of Clinical Pharmacology·Nynke Gl JagerJason A Roberts
Apr 29, 2014·The Lancet Infectious Diseases·Jason A RobertsUNKNOWN International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the Europe
Sep 15, 2016·Medizinische Klinik, Intensivmedizin und Notfallmedizin·A BrinkmannO R Frey
Mar 28, 2009·The Lancet Infectious Diseases·Baek-Nam KimDavid L Paterson
Oct 21, 2015·Antimicrobial Agents and Chemotherapy·Mohd H Abdul-AzizChristine E Staatz
Apr 26, 2019·Journal of Veterinary Emergency and Critical Care·Samuel D Stewart, Sarah Allen
Mar 11, 2016·Expert Opinion on Drug Safety·Kerina J DennyJeffrey Lipman
Oct 23, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Mei XuePeng Li
Sep 18, 2020·International Journal of Antimicrobial Agents·Suzanne L ParkerJason A Roberts
Jul 28, 2021·Expert Review of Clinical Pharmacology·Quyen TuJason A Roberts
Aug 16, 2021·The Journal of Antimicrobial Chemotherapy·Arthur HosmannMarkus Zeitlinger
Oct 7, 2021·Journal of Clinical Pharmacology·Katie B LandmesserDavid S Burgess

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.